Longevity Biotech has secured a Nasdaq listing through a $180 million SPAC (Special Purpose Acquisition Company) deal, according to recent reports from June 26, 2025125.
The company reached a business combination agreement with FutureTech II Acquisition Corp., a Delaware-based blank-check company, after a previously planned SPAC merger with Denali Capital Acquisition Corp. was scrapped earlier in the year5.
The merger will allow Longevity Biotech to operate publicly under the ticker symbol LBIO, with the transaction expected to close in Q4 20245.
The deal is set to provide $26.8 million in cash proceeds held in trust, with the potential for additional funding through a pre-transaction PIPE (private investment in public equity)5.
Longevity Biotech, headquartered in Bothell, Washington, focuses on the development of therapeutic technologies targeting age-related health conditions in areas such as ophthalmology, cardiovascular disease, and soft tissue reconstruction5.
Sources:
1. https://www.biospace.com/business/longevity-biotech-takes-roots-on-nasdaq-with-180m-spac-deal
2. https://www.biospace.com/press-releases/reviva-pharmaceuticals-holdings-inc-announces-pricing-of-10-million-public-offering
5. https://longevity.technology/news/try-try-again-longevity-biotech-targets-public-listing-via-spac-for-the-second-time/